Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, is excited to announce that its X-PACT 101 Phase 1 Clinical Trial is now open to patients with all Solid Tumors types. The phase 1 study of its X-Ray Activation of Psoralen Cancer Treatment system (X-PACT) in Breast, Melanoma, Sarcoma, and Head and Neck Cancers has now been expanded to include patients with any type of Solid Tumor.